翔宇医疗(688626) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥85,084,216, representing a decrease of 15.57% compared to the same period last year [6] - Net profit attributable to shareholders was ¥9,477,068.41, down 72.25% year-over-year [6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥5,008,421.84, a decline of 82.69% compared to the previous year [6] - Basic and diluted earnings per share were both ¥0.06, down 71.43% year-over-year [6] - Net profit for Q1 2022 was ¥8,332,824.99, a decline of 75.5% from ¥33,973,422.33 in Q1 2021 [32] - Earnings per share for Q1 2022 was ¥0.06, down from ¥0.21 in Q1 2021 [32] - Operating profit for Q1 2022 was ¥12,978,501.28, down 50.5% from ¥26,215,491.98 in Q1 2021 [49] - Net profit for Q1 2022 was ¥11,031,290.26, a decline of 50.0% compared to ¥22,072,885.83 in Q1 2021 [52] - The total comprehensive income for Q1 2022 was ¥8,332,824.99, significantly lower than ¥33,973,422.33 in Q1 2021 [32] - The total comprehensive income for Q1 2022 was ¥11,031,290.26, which is the same as the net profit, reflecting no other comprehensive income items [52] Cash Flow - The net cash flow from operating activities was -¥24,005,795.51, a significant decrease of 564.24% year-over-year [6] - Cash flow from operating activities in Q1 2022 was negative at -¥22,746,809.97, compared to a positive cash flow of ¥11,484,771.87 in Q1 2021 [54] - The company reported a decrease in cash received from operating activities, totaling 106,200,506.73 RMB compared to 126,169,228.08 RMB previously [38] - The company reported a total cash inflow from operating activities of ¥104,153,856.12 in Q1 2022, down from ¥114,147,244.76 in Q1 2021 [54] - Total cash inflow from investment activities was 596,530,207.27 RMB, while cash outflow was 649,477,003.19 RMB, resulting in a net cash flow of -52,946,795.92 RMB [38] - Cash and cash equivalents at the end of the period amounted to 749,152,830.61 RMB, down from 1,506,843,837.25 RMB in the previous period [40] Research and Development - Research and development expenses totaled ¥18,405,732.79, an increase of 43.48% compared to the same period last year [8] - R&D expenses accounted for 21.63% of operating revenue, up 8.90 percentage points year-over-year [8] - Research and development expenses rose to ¥18,405,732.79 in Q1 2022, compared to ¥12,827,992.23 in Q1 2021, reflecting a 43.7% increase [31] - Research and development expenses for Q1 2022 were ¥10,725,680.83, slightly up from ¥10,615,512.21 in Q1 2021 [46] - The company plans to continue strengthening R&D and sales investments, which has led to a temporary decline in net profit [11] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,154,381,313.03, a decrease of 1.29% from the end of the previous year [8] - As of March 31, 2022, the company's total current assets were approximately RMB 1.67 billion, a decrease from RMB 1.72 billion at the end of 2021 [23] - The company's cash and cash equivalents decreased to approximately RMB 751.49 million from RMB 829.62 million at the end of 2021, representing a decline of about 9.4% [23] - The company's total liabilities decreased from RMB 181.42 million to RMB 145.75 million, a reduction of approximately 19.7% [27] - The company's total assets as of March 31, 2022, were approximately RMB 2.15 billion, down from RMB 2.18 billion at the end of 2021 [27] - The company's accounts payable decreased significantly from RMB 33.15 million to RMB 21.47 million, a decline of about 35.3% [27] - Total liabilities amounted to ¥200,466,646.03, down from ¥236,967,892.99 in the previous year [31] - Total liabilities rose to 256,527,854.75 RMB compared to 232,375,085.17 RMB in the previous period [44] Intellectual Property - In Q1 2022, the company obtained 9 new medical device registration certificates, bringing the total to 189 [18] - The company added 104 new patents in Q1 2022, with a cumulative total of 1,155 patents [18] - The company reported a total of 88 new applications for various intellectual properties in Q1 2022, with 141 granted, bringing cumulative totals to 1,977 applications and 1,370 granted [19]